Literature DB >> 10078490

A cluster of transfusion-associated babesiosis cases traced to a single asymptomatic donor.

J Dobroszycki1, B L Herwaldt, F Boctor, J R Miller, J Linden, M L Eberhard, J J Yoon, N M Ali, H B Tanowitz, F Graham, L M Weiss, M Wittner.   

Abstract

CONTEXT: The risk of acquiring babesiosis by blood transfusion is largely unknown since in areas where it is endemic it is often an asymptomatic infection.
OBJECTIVE: To investigate and treat a cluster of blood transfusion-associated babesiosis cases.
DESIGN: Case series and epidemiologic investigation.
SETTING: Urban inner-city hospital. PATIENTS: Six persons who received Babesia microti-infected blood components from a donor. MAIN OUTCOME MEASURE: Diagnosis and successful therapy of babesiosis following transfusion.
RESULTS: Six individuals (1 adult, 1 child, and 4 neonates) were exposed to products from a single blood donation by an asymptomatic Babesia-infected donor. Three of the 6 exposed patients became parasitemic. Polymerase chain reaction testing, animal inoculation studies, and indirect immunofluorescent antibody testing were used to confirm the presence of Babesia microti in the donor's blood and to establish the presence of infection in 3 of the 6 recipients. The 3 infected recipients and 1 additional recipient were treated without incident.
CONCLUSION: Physicians should consider babesiosis in the differential diagnosis of a febrile hemolytic disorder after blood transfusion. Prompt diagnosis is important since babesiosis is responsive to antibiotic therapy and, untreated, can be a fatal disease in certain risk groups.

Entities:  

Mesh:

Year:  1999        PMID: 10078490     DOI: 10.1001/jama.281.10.927

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  14 in total

Review 1.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Transfusion-associated babesiosis with an atypical time course after nonmyeloablative transplantation for sickle cell disease.

Authors:  Christopher M Cirino; Susan F Leitman; Esther Williams; Daniel Fedorko; Tara N Palmore; Amy Klion; Christian Ockenhouse; Courtney Fitzhugh; John F Tisdale; Matthew M Hsieh
Journal:  Ann Intern Med       Date:  2008-05-20       Impact factor: 25.391

3.  Transfusion-acquired, autochthonous human babesiosis in Japan: isolation of Babesia microti-like parasites with hu-RBC-SCID mice.

Authors:  A Saito-Ito; M Tsuji; Q Wei; S He; T Matsui; M Kohsaki; S Arai; T Kamiyama; K Hioki; C Ishihara
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

4.  Transfusion-transmitted babesiosis in Ontario: first reported case in Canada.

Authors:  K C Kain; S B Jassoum; I W Fong; B Hannach
Journal:  CMAJ       Date:  2001-06-12       Impact factor: 8.262

Review 5.  Laboratory-acquired parasitic infections from accidental exposures.

Authors:  B L Herwaldt
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Serological expression cloning of novel immunoreactive antigens of Babesia microti.

Authors:  M J Lodes; R L Houghton; E S Bruinsma; R Mohamath; L D Reynolds; D R Benson; P J Krause; S G Reed; D H Persing
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 7.  Cultivation of Babesia and Babesia-like blood parasites: agents of an emerging zoonotic disease.

Authors:  Frederick L Schuster
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

8.  Cellular immunity, but not gamma interferon, is essential for resolution of Babesia microti infection in BALB/c mice.

Authors:  Michael L Clawson; Natalia Paciorkowski; T V Rajan; Carson La Vake; Conny Pope; Morgan La Vake; Stephen K Wikel; Peter J Krause; Justin D Radolf
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

9.  A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240].

Authors:  Finlay A McAlister; Miriam Fradette; Michelle Graham; Sumit R Majumdar; William A Ghali; Randall Williams; Ross T Tsuyuki; James McMeekin; Jeremy Grimshaw; Merril L Knudtson
Journal:  Implement Sci       Date:  2006-05-06       Impact factor: 7.327

10.  Probable congenital babesiosis in infant, new jersey, USA.

Authors:  Sonia Sethi; David Alcid; Hemant Kesarwala; Robert W Tolan
Journal:  Emerg Infect Dis       Date:  2009-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.